Regenerative craniofacial implant manufacturer OssDsign has amassed $19.7m altogether as it prepares to take its products based on Karolinska and Uppsala university research into new markets.

OssDsign, a Sweden-based developer of regenerative implants founded on research from Karolinska University Hospital and Uppsala University, closed a SKr64m ($6.9m) private placement on Tuesday backed by investment manager Alto Invest.
The round also featured unnamed Swedish private investors.
Founded in 2011 as Oss-Q, OssDsign designs and manufactures healing implants for bone defects made from titanium and a calcium phosphate material that has regenerative properties.
Each OssDsign implant is custom-built for the individual patient through 3D printing and computer-assisted design technologies. The company’s products currently include implants for cranial and facial defects in the skull.
OssDsign plans to list on the Nasdaq First North stock exchange later in 2019 and will use capital from the private placement to enter new markets including Japan, where it will complete regulatory and pre-marketing activities.
Karolinska Institute investment arm Karolinska Development currently owns a 25% fully-diluted stake in OssDsign,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?